Saffron, the stigmas of Crocus sativus L., has been used extensively in traditional herbal medicine. Since several years, the research interest in this plant is intense. Thus numerous clinical trials of saffron supplements (in contrast to the spice, supplements are affordable [they use different parts of the plant]) have been published. Almost all of them yield positive results (this invariably makes me suspicious!).
The purpose of this 2-arm, 12-wk, parallel-group, randomized, double-blind, placebo-controlled trial was to examine the effects of supplementation with a saffron extract (Affron) on mood and sleep in adults experiencing subclinical depressive symptoms. 202 adults aged 18-70 with depressive symptoms were supplemented with either 28 mg saffron daily or a placebo. Outcome measures included the Depression, Anxiety, and Stress Scale – 21, Sleep Disturbance and Sleep-Related Impairment Scale, World Health Organization-Five Well-Being Scale, and daily depression, stress, and anxiety ratings.
On the primary outcome measure, compared to the placebo, saffron was associated with greater improvements in the Depression, Anxiety, and Stress scale – 21 depression score (β: -2.92 points; 95% confidence interval: -5.13, -0.71 points; Cohen’s d = 0.39). 72% of participants in the saffron group achieved a clinically significant change (a reduction of ≥ 7 points) compared to 54.3% of participants in the placebo group (P = 0.010). However, in the other secondary outcomes, there was no evidence of between-group differences. In exploratory analyses across various strata and assumptions, improvements in sleep disturbances (β: -2.72 points; 95% confidence interval: -4.99, -0.46 points; Cohen’s d = 0.44) were identified in a subset of participants with a greater severity of sleep disturbance. There were no serious adverse reactions reported.
The authors concluded that this study, the largest conducted to date on saffron, provides evidence supporting the beneficial effects of 3 mo of saffron supplementation on depressive symptoms in adults. Large placebo responses were evident in this study, which require consideration in future trials.
As mentioned above, the body of evidence suggesting that saffron is effective for a surprisingly wide range of conditions is impressive. I looked with some skepticism at some of these studies and have to say that many are of decent or even good scientific quality.
Could it be that we have in saffron a plant-based treatment that shows real promise?
WATCH THIS SPACE!
2 Responses to The Effects of a Saffron on Mood and General Wellbeing in Adults Experiencing Low Mood
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
A decent paella or risotto alla milanese always makes me feel better.
The unequivocally validation of Omega-3 fatty acids on human inflammatory status and consequential impact of mental, physical, emotional health and resilience must be studied using omega-3 sources that are more akin to oily fish, rather than omega-3 isolates. The preferred research omega-3 sources must have included in the formulation polyphenols that replaces the phlorotannins chaperones that protected these lability unsaturated fatty acids from oxidation the fishe’s circulation. The inclusion of cold pressed olive from pre-harvested Picual olives provides the polyphenol chaperones that protect the omega-3 fatty acids, derived from small pelagic fishes, in the bottles, in the human systemic circulation long enough for incorporation into the red blood cell membranes and other membranes INTACT; Sintef studies confirm this. Using fish oil/oilive oil combinations that simulate the oily fish will give consistent results showing the benefits of omega-3 fatty acids, even more superior to pharmaceutically synthesised versions; replicate nature as closely as possible, less the matrix, and experience consistency in trial results across the board. If you are in need of the brand of choice that has a white paper published in high impact lipid journals; this study’s utilised data from over 590,000 patients.